Nanologica
0.42 SEK
+1.22 %
Less than 1K followers
NICA
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Nanologica
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 10.2 | 16.1 | 12.9 | 1.6 | 1.4 | 14.5 | 21.1 |
| growth-% | 57.8 % | -20.0 % | -87.9 % | -7.7 % | 909.7 % | 45.3 % | |
| EBITDA | -15.9 | -13.9 | -85.5 | -39.0 | -50.6 | -43.7 | -34.4 |
| EBIT | -19.2 | -19.6 | -40.7 | -50.9 | -70.0 | -59.3 | -46.8 |
| Profit before taxes | -19.6 | -22.2 | -44.8 | -55.2 | -75.2 | -65.6 | -51.3 |
| Net income | -19.6 | -22.2 | -44.8 | -55.2 | -75.2 | -65.6 | -51.3 |
| EPS | -1.12 | -0.88 | -1.51 | -1.74 | -1.97 | -1.31 | -0.57 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -155.4 % | -86.1 % | -662.2 % | -2,499.4 % | -3,513.9 % | -300.6 % | -162.6 % |
| EBIT-% | -188.0 % | -121.3 % | -315.1 % | -3,259.6 % | -4,858.3 % | -407.6 % | -221.5 % |
| ROE | -475.3 % | -23.9 % | -86.9 % | -75.5 % | 3,955.8 % | -88.6 % | -226.5 % |
| ROI | -46.3 % | -15.2 % | -45.6 % | -35.7 % | -97.1 % | -45.9 % | -58.2 % |